Eribulin Mesylate Combined with Local Treatment for Brain Metastasis from Breast Cancer: Two Case Reports / 한국유방암학회지
Journal of Breast Cancer
;
: 214-217, 2016.
Article
in English
| WPRIM
| ID: wpr-166629
ABSTRACT
The prognosis associated with brain metastasis arising from breast cancer is very poor. Eribulin is a microtubule dynamic inhibitor synthesized from halichondrin B, a natural marine product. In a phase III study (EMBRACE), eribulin improved overall survival in patients with heavily pretreated metastatic breast cancers. However, these studies included few patients with brain metastases. Metastatic brain tumors (MBT) were detected during first-line palliative chemotherapy in a 43-year-old woman with breast cancer metastasis to the lung and mediastinal nodes; the genetic subtype was luminal B-like human epidermal growth factor receptor 2 (HER2)-negative. Whole brain radiotherapy (WBRT) followed by eribulin treatment continuously decreased the size, and induced regression, of the MBT with systemic disease stability for 12 months. Another 48-year-old woman with metastatic breast cancer (HER2+ subtype) presented with MBT. Following surgical resection of the tumor, eribulin with concurrent WBRT showed regression of the MBT without systemic progression for 18 months.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Phenobarbital
/
Prognosis
/
Radiotherapy
/
Brain
/
Brain Neoplasms
/
Breast
/
Breast Neoplasms
/
Mesylates
/
Drug Therapy
/
ErbB Receptors
Type of study:
Prognostic study
Limits:
Adult
/
Female
/
Humans
Language:
English
Journal:
Journal of Breast Cancer
Year:
2016
Type:
Article
Similar
MEDLINE
...
LILACS
LIS